INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ — A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (LLY) in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia’s intellectual property, and while they denied Lilly’s smaller counterclaim, ruled that Lilly is not liable for damages. “We’re pleased with the panel’s decision,” said Michael J. Harrington, Lilly’s senior vice president and general counsel.

source https://finance.yahoo.com/news/arbitration-panel-rules-favor-lilly-005900094.html?.tsrc=rss